SETD1A and breast cancer: Data analysis of patients receiving tamoxifen monotherapy for more than five years revealed that SETD1A was strongly correlated with poor prognosis, and depletion of SETD1A in TamR BC cells led to alterations in the proliferation, migration, and invasion of these cells.